|
|
 |
| |
Shareholder Information |
THE ACTELION ANNUAL REPORT 2003 |
|
|
|
| |
|
|
|
|
|
|
| Share price |
| |
The following table shows the reported high and low quarterly closing share price of the Actelion shares on the SWX New Market during the year 2003.
|
|
|
| |
| |
|
| | | High | | Low | |
| First Quarter | | 67.5 | | 54 | |
| Second Quarter | | 99.5 | | 65 | |
| Third Quarter | | 114 | | 88.3 | |
| Fourth Quarter | | 134 | | 109 | |
|
|
| |
|
|
|
|
|
|
On 31 December 2003, the last reported closing share price was CHF 133.5 and market capitalization of Actelion Ltd was CHF 2.90 billion, compared with a share price of CHF 61 and market capitalization of CHF 1.29 billion the previous year. The total number of shareholders on 31 December 2003 was 4604.
|
|
|
| |
|
|
|
|
|
|
| Listing |
| |
Actelion Ltd is organized under Swiss law and is the holding company of the Actelion Group. The company’s initial equity funding was provided in 1998 and 1999 in two separate rounds of financing totaling CHF 66 million.
The registered shares of Actelion Ltd have been listed on the SWX New Market since April 6, 2000 (symbol: ATLN). A total of 1,000,000 primary shares were placed at the company’s Initial Public Offering at the price of CHF 260 per share raising CHF 246.1 million. On June 20, 2001, Actelion Ltd announced a 4:1 split in its shares.
On September 9th, 2002 Actelion listed the company’s registered shares on the SWX Main Market. The SWX Swiss Exchange waived the requirement for a listing prospectus. The trading symbol remains the same and the company will continue to report full quarterly figures.
|
|
|
| |
| |
|
| Investor Relations Calendar 2004 | |
| March 2 | | Media/Analyst Conference | |
| April 27 | | Q1 2004 Results | |
| April 30 | | Annual General Meeting of Shareholders | |
| July 27 | | Half Year 2004 Results | |
| October 26 | | Nine months 2004 Results | |
|
|
| |
|
|
|
|
|
|
| Board of Directors |
| |
Werner Henrich
Senior Vice President, F. Hoffmann-La Roche
(Pharmaceuticals Division)
Rudolf Maag
Former CEO, Synthes-Stratec, Inc.
Fred J. Meyer
Retired Vice Chairman, Omnicom Group
| | André J. Mueller
Senior Vice President
Joël Besse
Senior Principal, Atlas Venture
Jean-Paul Clozel
Founder, Chief Executive Officer
Robert E. Cawthorn Chairman
Retired Chairman and CEO,
Rhône-Poulenc-Rorer
|
|
|
|
| |
|
|
|
|
|
|
| Scientific Advisory Board |
| |
Joël Ménard
Professor of Public Health, University Pierre et Marie Curie, Paris
Donald Hilvert
Professor of Chemistry at the Swiss Federal Institute of Technology (ETH), Zürich
| | Richard Tsien
Professor of the Department of
Molecular and Cellular Physiology,
Stanford University, Palo Alto
Craig Pratt
Professor of Medicine and Cardiology,
Baylor College of Medicine, Houston |
|
|
|
| |
|
|
|
|
|
|
| Business Executive Board |
| |
Jean-Paul Clozel
Founder, Chief Executive Officer
Simon Buckingham
President, Head of US, Canada, Asia Pacific
Isaac Kobrin
Senior Vice President,
Head of Clinical
Development
| | Andrew J. Oakley
Vice President, Chief Financial Officer
Christian Chavy
President, Head of Europe, Middle East,
Latin America
Louis de Lassence
Vice President, Head of Corporate Services
Satoshi Tanaka
President and Representative Director, Japan |
|
|
|
| |
|
|
|
|
|
|
| Senior Management |
| |
Frédéric Bodin
Senior Vice President, Head of International Medical Marketing
Martine Clozel
Senior Vice President, Head of Drug Discovery Pharmacology & Preclinical Development
| | Walter Fischli
Founder, Senior Vice President,
Head of Drug Discovery Molecular
Biology & Biochemistry
André J. Mueller
Senior Vice President |
|
|
|
|
